- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07278336
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 as a Monotherapy and in Combination in Adult Subjects With Ovarian Cancer
Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with other anticancer drugs, in participants with ovarian cancer.
ABBV901 is an investigational drug for the treatment of ovarian cancer. This study has 6 parts where participants will receive ABBV-901, alone or in combination with other anticancer therapies. Around 285 participants will be enrolled in the study at approximately 45 sites around the world.
In part 1, participants will receive escalating doses of intravenous (IV) ABBV-901 alone. In part 2, participants will receive 1 of 3 doses of IV ABBV-901 alone to determine the optimized dose. In part 3, participants will receive escalating doses of IV ABBV-901 in combination with IV bevacizumab. In part 4, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV bevacizumab. in Part 5, participants will receive escalating doses of IV ABBV-901 in combination with IV carboplatin and IV bevacizumab and in part 6, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV carboplatin and IV bevacizumab. The total study duration will be approximately 3 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: ABBVIE CALL CENTER
- Numéro de téléphone: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Lieux d'étude
-
-
New South Wales
-
Blacktown, New South Wales, Australie, 2148
- Recrutement
- Blacktown Hospital /ID# 282426
-
-
Victoria
-
Clayton, Victoria, Australie, 3168
- Recrutement
- Monash Health - Monash Medical Centre - Clayton /ID# 281468
-
Melbourne, Victoria, Australie, 3000
- Recrutement
- Peter MacCallum Cancer Centre. /ID# 281751
-
-
-
-
-
Barcelona, Espagne, 08035
- Recrutement
- Hospital Universitari Vall d Hebron /ID# 280442
-
Madrid, Espagne, 28040
- Recrutement
- Hospital Universitario Fundacion Jimenez Diaz /ID# 280440
-
Madrid, Espagne, 28050
- Recrutement
- Hospital Universitario HM Sanchinarro /ID# 280439
-
-
Madrid
-
Majadahonda, Madrid, Espagne, 28222
- Recrutement
- Hospital Universitario Puerta de Hierro - Majadahonda /ID# 280459
-
-
-
-
Pays de la Loire Region
-
Saint-Herblain, Pays de la Loire Region, France, 44805
- Recrutement
- Institut De Cancerologie De L'Ouest - Site Rene Gauducheau /ID# 280684
-
-
Rhone
-
Lyon, Rhone, France, 69373
- Recrutement
- Centre Leon Berard /ID# 280575
-
-
-
-
-
Haifa, Israël, 3109601
- Recrutement
- Rambam Health Care Campus /ID# 278418
-
Jerusalem, Israël, 91120
- Recrutement
- Hadassah Medical Center-Hebrew University /ID# 278420
-
-
Tel Aviv
-
Ramat Gan, Tel Aviv, Israël, 5265601
- Recrutement
- The Chaim Sheba Medical Center /ID# 278416
-
-
-
-
Chiba
-
Kashiwa-shi, Chiba, Japon, 277-8577
- Recrutement
- National Cancer Center Hospital East /ID# 278604
-
-
Saitama
-
Hidaka, Saitama, Japon, 350-1298
- Recrutement
- Saitama Medical University International Medical Center /ID# 278437
-
-
Shizuoka
-
Sunto-gun, Shizuoka, Japon, 411-8777
- Recrutement
- Shizuoka Cancer Center /ID# 278538
-
-
-
-
-
Lisbon, Le Portugal, 1649-035
- Recrutement
- Unidade Local de Saude de Santa Maria /ID# 280296
-
Porto, Le Portugal, 4200-072
- Recrutement
- Instituto Portugues de Oncologia do Porto Francisco Gentil /ID# 280293
-
-
-
-
-
Taipei, Taïwan, 112
- Recrutement
- Taipei Veterans General Hospital /ID# 281349
-
Taipei, Taïwan, 100
- Recrutement
- National Taiwan University Hospital /ID# 280701
-
-
-
-
California
-
Duarte, California, États-Unis, 91010
- Recrutement
- City of Hope National Medical Center /ID# 281381
-
Irvine, California, États-Unis, 92618
- Recrutement
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 280914
-
-
Colorado
-
Denver, Colorado, États-Unis, 80218
- Recrutement
- Sarah Cannon Research Institute at HealthONE /ID# 278785
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- Recrutement
- University of Chicago Medical Center /ID# 278295
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68198
- Recrutement
- University Of Nebraska Medical Center /ID# 281020
-
-
Texas
-
San Antonio, Texas, États-Unis, 78229
- Recrutement
- NEXT Oncology - San Antonio /ID# 278606
-
-
Utah
-
West Valley City, Utah, États-Unis, 84119
- Recrutement
- Start Mountain Region /ID# 278609
-
-
Virginia
-
Fairfax, Virginia, États-Unis, 22031
- Recrutement
- Next Virginia /ID# 278607
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Diagnosis of an advanced or unresectable malignant high grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC), fallopian tube or primary peritoneal cancer by histology (World Health Organization [WHO] criteria).
- Participants enrolled in backfill (Part 1) must provide consent to paired fresh biopsies which are pretreatment and on-treatment tumor biopsies from the same tumor lesion.
For Parts 1-4:
- Participants must be considered platinum resistant or platinum ineligible. Platinum resistant disease is defined as radiographic progression within 6 months (up to 182 days) after the last dose of the most recent platinum therapy).
For Parts 5-6:
- Participants will have platinum-sensitive disease defined as radiographic progression > 6 months from last dose of platinum-based chemotherapy. Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression.
Exclusion Criteria:
- Ovarian Cancer (OC) with histologies other than high grade serous OC including endometrioid, low grade, mucinous, carcinosarcoma or sarcomatous histology, mixed tumors or low grade/borderline ovarian tumor.
- Participants with platinum refractory disease.
- Prior therapy with an antibody-drug conjugate containing a topoisomerase inhibitor.
- Prior history of Grade >= 2 interstitial lung disease (ILD) or pneumonitis.
- Prior history of Grade 2 >= 2 ILD or pneumonitis or any evidence of active ILD or pneumonitis on Screening chest computed tomography (CT) scan.
For Parts 3-6:
- History of Grade 3/4 adverse events that, in the opinion of the investigator, are attributed to bevacizumab.
- History of clinically significant cardiac disease including CHF Class II or higher NYHA; active coronary artery disease, MI within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted).
- Echocardiogram with ejection fraction <= 50% and no other clinically significant cardiac abnormalities that in the opinion of the investigator, would increase the participants susceptibility to cardiac toxicity.
For Parts 5-6:
- Participants who had prior allergic reaction to platinum containing compound.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Part 1: ABBV-901 Dose Escalation
Participants will receive escalating doses of ABBV-901 alone, as part of the approximately 3 year study duration. |
Intravenous (IV) |
|
Expérimental: Part 2: ABBV-901 Optimization Dose A
Participants will receive ABBV-901 dose A alone, as part of the approximately 3 year study duration. |
Intravenous (IV) |
|
Expérimental: Part 2: ABBV-901 Optimization Dose B
Participants will receive ABBV-901 dose B alone, as part of the approximately 3 year study duration. |
Intravenous (IV) |
|
Expérimental: Part 2: ABBV-901 Optimization Dose C
Participants will receive ABBV-901 dose C alone, as part of the approximately 3 year study duration. |
Intravenous (IV) |
|
Expérimental: Part 3: ABBV-901 + Bevacizumab Escalation
Participants will receive escalating doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration. |
Intravenous (IV) Intravenous (IV) |
|
Expérimental: Part 4: ABBV-901 + Bevacizumab Expansion
Participants will receive the recommended doses for expansion doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration. |
Intravenous (IV) Intravenous (IV) |
|
Expérimental: Part 5: ABBV-901 + Carboplatin + Bevacizumab Escalation
Participants will receive escalating doses of ABBV-901 in combination with Carboplatin & Bevacizumab, as part of the approximately 3 year study duration. |
Intravenous (IV) Intravenous (IV) Intravenous (IV) |
|
Expérimental: Part 6: ABBV-901 + Carboplatin + Bevacizumab Expansion
Participants will receive the recommended doses for expansion doses of ABBV-901 in combination with Carboplatin & Bevacizumab, as part of the approximately 3 year study duration. |
Intravenous (IV) Intravenous (IV) Intravenous (IV) |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants with Adverse Events (AE)
Délai: Up to Approximately 3 Years
|
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 3 Years
|
|
Overall Response (as assessed by the investigator)
Délai: Up to Approximately 3 Years
|
Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by the investigator. |
Up to Approximately 3 Years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall Response (as assessed by independent central review)
Délai: Up to Approximately 3 Years
|
Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by independent central review (ICR). |
Up to Approximately 3 Years
|
|
Duration of Response (DOR)
Délai: Up to Approximately 3 Years
|
DOR is defined for participants achieving a confirmed PR or better as the time from the initial response of PR (or better) per investigator review according to RECIST Version 1.1 criteria to disease progression or death of any cause, whichever occurs earlier. |
Up to Approximately 3 Years
|
|
Progression-free survival (PFS)
Délai: Up to Approximately 3 Years
|
PFS is defined as time from first study treatment to a documented disease progression according to RECIST Version 1.1 (or other assessment criteria), as determined by the investigator, or death due to any cause, whichever occurs earlier. |
Up to Approximately 3 Years
|
|
Overall Survival (OS)
Délai: Up to Approximately 3 Years
|
OS is defined as time from first study treatment to death due to any cause. |
Up to Approximately 3 Years
|
|
Disease Control Rate
Délai: Up to Approximately 3 Years
|
Disease Control Rate is defined as the percentage of participants with best overall response (BOR) of stable disease (SD), PR or better per investigator review according to RECIST version 1.1 criteria. |
Up to Approximately 3 Years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: ABBVIE INC., AbbVie
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies génitales
- Maladies du système endocrinien
- Tumeurs urogénitales
- Tumeurs par site
- Tumeurs
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladies génitales, femme
- Tumeurs des glandes endocrines
- Maladies ovariennes
- Maladies annexielles
- Tumeurs génitales, femme
- Troubles gonadiques
- Tumeurs ovariennes
- Acides aminés, peptides et protéines
- Protéines
- Produits chimiques organiques
- Anticorps, monoclonal, humanisé
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Complexes de coordination
- Bévacizumab
- Carboplatine
Autres numéros d'identification d'étude
- M25-760
- 2025-522209-40-00 (Ctis)
- 2025 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .